Your browser doesn't support javascript.
loading
Differential Recognition of Mycobacterium tuberculosis-Specific Epitopes as a Function of Tuberculosis Disease History.
Scriba, Thomas J; Carpenter, Chelsea; Pro, Sebastian Carrasco; Sidney, John; Musvosvi, Munyaradzi; Rozot, Virginie; Seumois, Grégory; Rosales, Sandy L; Vijayanand, Pandurangan; Goletti, Delia; Makgotlho, Edward; Hanekom, Willem; Hatherill, Mark; Peters, Bjoern; Sette, Alessandro; Arlehamn, Cecilia S Lindestam.
Afiliación
  • Scriba TJ; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Carpenter C; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Pro SC; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Sidney J; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Musvosvi M; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Rozot V; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Seumois G; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Rosales SL; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Vijayanand P; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Goletti D; 3 Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases, Rome, Italy.
  • Makgotlho E; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Hanekom W; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Hatherill M; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Peters B; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Sette A; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
  • Arlehamn CSL; 2 Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.
Am J Respir Crit Care Med ; 196(6): 772-781, 2017 09 15.
Article en En | MEDLINE | ID: mdl-28759253
RATIONALE: Individuals with a history of tuberculosis (TB) disease are at elevated risk of disease recurrence. The underlying cause is not known, but one explanation is that previous disease results in less-effective immunity against Mycobacterium tuberculosis (Mtb). OBJECTIVES: We hypothesized that the repertoire of Mtb-derived epitopes recognized by T cells from individuals with latent Mtb infection differs as a function of previous diagnosis of active TB disease. METHODS: T-cell responses to peptide pools in samples collected from an adult screening and an adolescent validation cohort were measured by IFN-γ enzyme-linked immunospot assay or intracellular cytokine staining. MEASUREMENTS AND MAIN RESULTS: We identified a set of "type 2" T-cell epitopes that were recognized at 10-fold-lower levels in Mtb-infected individuals with a history of TB disease less than 6 years ago than in those without previous TB. By contrast, "type 1" epitopes were recognized equally well in individuals with or without previous TB. The differential epitope recognition was not due to differences in HLA class II binding, memory phenotypes, or gene expression in the responding T cells. Instead, "TB disease history-sensitive" type 2 epitopes were significantly (P < 0.0001) more homologous to sequences from bacteria found in the human microbiome than type 1 epitopes. CONCLUSIONS: Preferential loss of T-cell reactivity to Mtb epitopes that are homologous to bacteria in the microbiome in persons with previous TB disease may reflect long-term effects of antibiotic TB treatment on the microbiome.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Epítopos de Linfocito T / Mycobacterium tuberculosis / Antígenos Bacterianos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Epítopos de Linfocito T / Mycobacterium tuberculosis / Antígenos Bacterianos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica